Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Life Sci Alliance ; 7(2)2024 02.
Article in English | MEDLINE | ID: mdl-37957015

ABSTRACT

Deregulation of the Hippo pathway is a driver for cancer progression and treatment resistance. In the context of gastric cancer, YAP1 is a biomarker for poor patient prognosis. Although genomic tumor profiling provides information of Hippo pathway activation, the present study demonstrates that inhibition of Yap1 activity has anti-tumor effects in gastric tumors driven by oncogenic mutations and inflammatory cytokines. We show that Yap1 is a key regulator of cell metabolism, proliferation, and immune responses in normal and neoplastic gastric epithelium. We propose that the Hippo pathway is targetable across gastric cancer subtypes and its therapeutic benefits are likely to be mediated by both cancer cell-intrinsic and -extrinsic mechanisms.


Subject(s)
Stomach Neoplasms , Humans , Stomach Neoplasms/genetics , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Tumor Microenvironment , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Hippo Signaling Pathway , STAT3 Transcription Factor/metabolism
2.
PLoS One ; 10(9): e0136817, 2015.
Article in English | MEDLINE | ID: mdl-26334628

ABSTRACT

The development of antigen-targeted therapeutics is dependent on the preferential expression of tumor-associated antigens (TAA) at targetable levels on the tumor. Tumor-associated antigens can be generated de novo or can arise from altered expression of normal basal proteins, such as the up-regulation of human epidermal growth factor receptor 2 (Her2/ErbB2). To properly assess the development of Her2 therapeutics in an immune tolerant model, we previously generated a transgenic mouse model in which expression of the human Her2 protein was present in both the brain and mammary tissue. This mouse model has facilitated the development of Her2 targeted therapies in a clinically relevant and suitable model. While heterozygous Her2+/- mice appear to develop in a similar manner to wild type mice (Her2-/-), it has proven difficult to generate homozygous Her2+/+ mice, potentially due to embryonic lethality. In this study, we performed whole genome sequencing to determine if the integration site of the Her2 transgene was responsible for this lethality. Indeed, we report that the Her2 transgene had integrated into the Pds5b (precocious dissociation of sisters) gene on chromosome 5, as a 162 copy concatemer. Furthermore, our findings demonstrate that Her2+/+ mice, similar to Pds5b-/- mice, are embryonic lethal and confirm the necessity for Pds5b in embryonic development. This study confirms the value of whole genome sequencing in determining the integration site of transgenes to gain insight into associated phenotypes.


Subject(s)
DNA-Binding Proteins/genetics , Genes, Lethal , Genes, erbB-2 , Homozygote , Transcription Factors/genetics , Animals , Cell Line, Tumor , Chromosome Mapping , Exons , Fetal Death , Humans , Mice , Mice, Transgenic , Phenotype
3.
Proc Natl Acad Sci U S A ; 102(21): 7659-64, 2005 May 24.
Article in English | MEDLINE | ID: mdl-15897450

ABSTRACT

The zinc finger protein LMO4 is overexpressed in a high proportion of breast carcinomas. Here, we report that overexpression of a mouse mammary tumor virus (MMTV)-Lmo4 transgene in the mouse mammary gland elicits hyperplasia and mammary intraepithelial neoplasia or adenosquamous carcinoma in two transgenic strains with a tumor latency of 13-18 months. To investigate cellular processes controlled by LMO4 and those that may be deregulated during oncogenesis, we used RNA interference. Down-regulation of LMO4 expression reduced proliferation of human breast cancer cells and increased differentiation of mouse mammary epithelial cells. Furthermore, small-interfering-RNA-transfected breast cancer cells (MDA-MB-231) had a reduced capacity to migrate and invade an extracellular matrix. Conversely, overexpression of LMO4 in noninvasive, immortalized human MCF10A cells promoted cell motility and invasion. Significantly, in a cohort of 159 primary breast cancers, high nuclear levels of LMO4 were an independent predictor of death from breast cancer. Together, these findings suggest that deregulation of LMO4 in breast epithelium contributes directly to breast neoplasia by altering the rate of cellular proliferation and promoting cell invasion.


Subject(s)
Breast Neoplasms/genetics , Gene Expression , Homeodomain Proteins/metabolism , Mammary Glands, Animal/pathology , Neoplasm Invasiveness/genetics , Transcription Factors/metabolism , Adaptor Proteins, Signal Transducing , Animals , Blotting, Western , Breast Neoplasms/metabolism , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation , DNA Primers , Female , Fluorescent Antibody Technique , Homeodomain Proteins/genetics , Humans , Hyperplasia/metabolism , Immunohistochemistry , LIM Domain Proteins , Mammary Glands, Animal/metabolism , Mammary Tumor Virus, Mouse , Mice , Mice, Inbred BALB C , Mice, Transgenic , New South Wales , RNA Interference , Risk Factors , Transcription Factors/genetics , Transfection , Transgenes/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...